Knight Therapeutics Inc. Share Price

Equities

GUD

CA4990531069

Pharmaceuticals

Market Closed - Toronto S.E. 01:30:00 20/07/2024 am IST 5-day change 1st Jan Change
5.73 CAD +0.35% Intraday chart for Knight Therapeutics Inc. +0.17% +10.40%

Financials

Sales 2024 * 35Cr 25Cr 2.11TCr Sales 2025 * 36Cr 26Cr 2.17TCr Capitalization 58Cr 42Cr 3.54TCr
Net income 2024 * 20L 14.55L 12Cr Net income 2025 * 1.3Cr 94.59L 79Cr EV / Sales 2024 * 1.68 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.63 x
P/E ratio 2024 *
156 x
P/E ratio 2025 *
41.7 x
Employees 725
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.54%
More Fundamentals * Estimated data
Dynamic Chart
1 day+0.35%
1 week+0.17%
Current month+1.06%
1 month+5.91%
3 months+0.17%
6 months+0.17%
Current year+10.40%
More quotes
1 week
5.68
Extreme 5.68
5.88
1 month
5.39
Extreme 5.39
5.88
Current year
5.13
Extreme 5.13
6.22
1 year
4.35
Extreme 4.35
6.22
3 years
4.28
Extreme 4.28
6.22
5 years
4.28
Extreme 4.28
8.88
10 years
4.28
Extreme 4.28
11.03
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 01/13/01
Founder 56 01/13/01
Director of Finance/CFO - 20/16/20
Members of the board TitleAgeSince
Director/Board Member 74 06/14/06
Founder 56 01/13/01
Director/Board Member 61 01/13/01
More insiders
Date Price Change Volume
19/24/19 5.73 +0.35% 38,591
18/24/18 5.71 -0.52% 56,069
17/24/17 5.74 -0.86% 53,713
16/24/16 5.79 -1.19% 34,577
15/24/15 5.86 +2.45% 39,307

Delayed Quote Toronto S.E., July 20, 2024 at 01:30 am IST

More quotes
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.73 CAD
Average target price
7.243 CAD
Spread / Average Target
+26.40%
Consensus